Abstract

Tyrosine kinases are involved in the pathogenesis of most cancers. However, few tyrosine kinases have been shown to have a well-defined pathogenetic role in lymphomas. The anaplastic lymphoma kinase (ALK) is the oncogene of most anaplastic large cell lymphomas (ALCL), driving transformation through many molecular mechanisms. In this Review, we will analyse how translocations or deregulated expression of ALK contribute to oncogenesis and how recent genetic or pharmacological tools, aimed at neutralizing its activity, can represent the basis for the design of powerful combination therapies.

Author affiliations

1. Center for Experimental Research and Medical Studies (CERMS), University of Torino, Via Santena 7, 10126, Italy.
2. Department of Biomedical Sciences and Human Oncology, University of Torino, 10126, Italy.
3. Department of Pathology and New York Cancer Center, New York University School of Medicine, New York, New York 10016, USA.

Correspondence to: Roberto Chiarle^1,2 Email: roberto.chiarle@unito.it

Correspondence to: Giorgio Inghirami^1,2,3 Email: giorgio.inghirami@unito.it

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.